Want to see AU:HMD full AI Analyst Report?
Top Page
HeraMED Ltd.
(Sydney:HMD)
Select Model
Select Model
Rating:44Neutral
Price Target:
AU$0.04
▼(-7.50% Downside)
Action:Reiterated
Date:06/04/26
The score is held down primarily by persistent losses and recurring negative operating/free cash flow (cash burn), alongside recent revenue contraction. A debt-free balance sheet with improved gross margin provides some support, but technical indicators remain weak-to-mixed and valuation signals are constrained by negative earnings and no dividend data.
Positive Factors
Focused maternal & fetal remote-monitoring product suite
HeraMED’s core business—connected devices and software for maternal and fetal health—aligns with durable structural trends toward remote, at‑home clinical monitoring and telehealth. This focus supports recurring clinical use cases and long-term demand from health systems and maternity care providers.
Negative Factors
Persistent negative operating and free cash flow
Consistent negative operating and free cash flow denotes ongoing cash burn and reliance on external funding or equity issuance to sustain operations. Over a 2–6 month horizon this raises liquidity and execution risk and limits the company’s ability to invest organically in commercialization or regulatory work.
Read all positive and negative factors
Positive Factors
Negative Factors
Focused maternal & fetal remote-monitoring product suite
HeraMED’s core business—connected devices and software for maternal and fetal health—aligns with durable structural trends toward remote, at‑home clinical monitoring and telehealth. This focus supports recurring clinical use cases and long-term demand from health systems and maternity care providers.
Read all positive factors
HeraMED Ltd. (HMD) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$44.03M
Dividend YieldN/A
Average Volume (3M)1.96M
Price to Earnings (P/E)―
Beta (1Y)1.94
Revenue Growth-19.47%
EPS Growth62.28%
CountryAU
Employees6
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,158,636,600
10 Day Avg. Volume1,195,844
30 Day Avg. Volume1,958,766
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)41.38
Price to Sales (P/S)131.32
P/FCF Ratio-10.53
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
HeraMED Ltd. Business Overview & Revenue Model
Company Description
HeraMED Limited and its associated entities are dedicated to the design, production, and sale of at-home fetal heart rate monitors and comprehensive pregnancy monitoring systems. These solutions are offered to consumers throughout Australia, Europ...
How the Company Makes Money
null...
HeraMED Ltd. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
46
Neutral
Cash Flow
21
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 195.77K | 225.49K | 413.19K | 215.81K | 83.68K |
| Gross Profit | 99.78K | 135.29K | 248.12K | -214.69K | -219.50K |
| EBITDA | -2.56M | -3.35M | -3.97M | -3.17M | -3.93M |
| Net Income | ― | -3.40M | -4.50M | -4.88M | -5.71M |
Balance Sheet | |||||
| Total Assets | 994.94K | 2.78M | 2.01M | 4.19M | 4.57M |
| Cash, Cash Equivalents and Short-Term Investments | 914.65K | 3.13M | 723.29K | 2.64M | 3.55M |
| Total Debt | 282.39K | 815.96K | 209.37K | 179.53K | 3.41M |
| Total Liabilities | 559.96K | 1.06M | 1.55M | 1.30M | 4.13M |
| Stockholders Equity | 621.27K | 1.72M | 466.70K | 2.88M | -105.66K |
Cash Flow | |||||
| Free Cash Flow | -2.44M | -2.98M | -5.57M | -3.20M | -3.20M |
| Operating Cash Flow | -2.44M | -2.98M | -5.57M | -2.52M | -3.12M |
| Investing Cash Flow | 0.00 | 0.00 | -2.05K | -690.78K | -85.43K |
| Financing Cash Flow | 1.27M | 6.88M | 2.96M | 2.54M | 4.88M |
HeraMED Ltd. Technical Analysis
Negative
0.04
Price Trends
0.04
Negative
0.04
Negative
0.04
Negative
Market Momentum
>-0.01
Positive
47.38
Neutral
26.19
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:HMD, the sentiment is Negative. The current price of 0.04 is above the 20-day moving average (MA) of 0.04, above the 50-day MA of 0.04, and above the 200-day MA of 0.04, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 47.38 is Neutral, neither overbought nor oversold. The STOCH value of 26.19 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:HMD.
HeraMED Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | AU$41.30B | 19.17 | 24.41% | 0.95% | 8.62% | 14.49% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | AU$21.97M | -0.50 | -165.13% | ― | 23.30% | -14.29% | |
44 Neutral | AU$44.03M | -9.15 | -547.06% | ― | -19.47% | 62.28% | |
43 Neutral | AU$3.12M | -1.56 | -358.43% | ― | -52.22% | 44.79% | |
42 Neutral | AU$43.95M | 550.00 | 0.48% | ― | 24.45% | ― | |
41 Neutral | AU$14.44M | -2.86 | -58.40% | ― | -7.00% | 44.55% |
* Healthcare Sector Average
AU:HMD
HeraMED Ltd.
0.04
0.03
216.67%
AU:CMP
Compumedics Limited
0.22
-0.06
-22.81%
AU:IPD
Impedimed Limited
0.01
-0.04
-72.55%
AU:UCM
Uscom Limited
0.01
>-0.01
-7.69%
AU:AT1
Atomo Diagnostics Ltd.
0.02
>-0.01
-20.00%
AU:RMD
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh
28.75
-10.59
-26.91%
HeraMED Ltd. Corporate Events
HeraMED Pilot with Lee Health Validates Digital-First Prenatal Care Model
Jul 13, 2026
HeraMED has completed Phase 1 of its Digital Pregnancy Journey pilot with U.S. provider Lee Health, testing the HeraCARE platform within a hybrid obstetrics model that blends virtual visits and remote monitoring. The six-month feasibility study, i...
HeraMED Issues 15 Million Unquoted Options in Capital Management Move
Jun 24, 2026
HeraMED Ltd. has notified the market of the issuance of 15 million unquoted options, each exercisable at $0.06 and expiring on June 24, 2029. The options form part of a previously announced transaction and will not be quoted on the ASX, indicating...
HeraMED Issues 4 Million Unquoted Options in New Equity Class
Jun 24, 2026
HeraMED Ltd. has notified the market of the issue of 4 million unquoted options, each exercisable at $0.06 and expiring on 24 June 2029, under a new class of securities. The move modestly expands the company’s pool of equity-based instrument...
HeraMED Seeks ASX Quotation for 1.15 Million New Shares
Jun 19, 2026
HeraMED Limited has applied to the Australian Securities Exchange for quotation of 1,150,000 new ordinary fully paid shares under its ASX code HMD. The new securities, issued on 19 June 2026, arise from the exercise or conversion of existing optio...
HeraMED Wins Strong Shareholder Backing as All AGM Resolutions Pass
May 21, 2026
HeraMED shareholders have backed the company’s strategic and governance settings at the 2026 annual general meeting, passing all resolutions put to the vote. The outcome underscores continued investor support for the medtech’s focus on...
HeraMED Adds 2.5 Million Shares to ASX Quotation
May 11, 2026
HeraMED Ltd. has applied to the ASX for quotation of 2.5 million new ordinary fully paid shares, expanding its listed securities under code HMD. The additional shares, issued on May 11, 2026, arise from the exercise or conversion of existing optio...
HeraMED Accelerates U.S. Push as Philips Partnership and Lee Health Pilot Gain Traction
Apr 30, 2026
HeraMED has reported a pivotal March 2026 quarter marked by advancing its U.S. commercial push for the HeraCARE platform through a deepening partnership with Philips and a promising pilot with Florida-based Lee Health. The company is transitioning...
HeraMED Director Timothy Chapman Granted 2.5 Million Performance Rights
Apr 27, 2026
HeraMED Ltd. has disclosed a change in director Timothy Chapman’s indirect interest in the company, lodged under ASX listing rule requirements. The notice details his holdings via Inverness Capital Pty Ltd, where he is a director, shareholde...
HeraMED Issues 3 Million Unquoted Options Under Employee Scheme
Apr 27, 2026
HeraMED Limited has issued 3,000,000 unquoted options under an employee incentive scheme, with various exercise prices and expiry dates, as notified in an Appendix 3G filing to the ASX. The new options, which will not be quoted on the exchange, fo...
HeraMED Issues 4 Million Unquoted Performance Rights Under Staff Incentive Plan
Apr 27, 2026
HeraMED Ltd. has notified the market that it will issue 4,000,000 unquoted performance rights under its employee incentive scheme, with an issue date of 21 April 2026. The move underscores the company’s ongoing use of equity-based remunerati...
HeraMED Sets May AGM as It Advances Digital Maternity Care Platform
Apr 21, 2026
HeraMED Limited, a digital health company specialising in remote maternity care, develops and markets the HeraCARE platform, which combines hardware, software, and data analytics to deliver integrated, cost-efficient prenatal and postpartum monito...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.